First-line metastatic colon or rectal cancer study with targeted drugs
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to join the study after signing informed consent, and you are at least 18 years old
- Your colon or rectal cancer is confirmed as adenocarcinoma and has spread (metastatic) with at least one measurable spot on a recent CT or MRI
- The cancer is mainly not treatable by surgery, or you cannot or do not want surgery
- Your tumor tests negative for RAS mutations (RAS wild-type) using a validated lab test
- You are well enough for treatment (ECOG performance status 0–2) and your blood, liver, and kidney tests meet minimum thresholds
- You have not had prior drug treatment for metastatic cancer (adjuvant chemo is allowed only if finished more than 3 months ago)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
This trial tests a new drug combination for people with colorectal cancer that has spread and cannot be removed by surgery. It compares the new drug plus standard chemotherapy against a placebo plus the same chemotherapy, to see if it helps shrink tumors and slow the disease.
This study tests a combination of two drugs (bevacizumab and adebrelimab) for people with a specific type of advanced colorectal cancer that has not responded to standard treatments. It aims to see if this combination can help control the cancer and improve outcomes.
This trial tests a combination of two drugs—bevacizumab and trifluridine/tipiracil—given together to see if it lowers the risk of a serious drop in white blood cells (neutropenia) in people with advanced colorectal cancer. The goal is to make treatment safer and more tolerable.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
This trial tests two different drug combinations for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if one combination works as well as the other, potentially offering a new option.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.